

Global Epidermolysis Bullosa Therapeutics Market Growth 2025-2031

<https://marketpublishers.com/r/G4FD14A7E168EN.html>

Date: January 2025

Pages: 115

Price: US\$ 3,660.00 (Single User License)

ID: G4FD14A7E168EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Epidermolysis Bullosa Therapeutics market size is predicted to grow from US\$ 1749 million in 2025 to US\$ 2338 million in 2031; it is expected to grow at a CAGR of 5.0% from 2025 to 2031.

United States market for Epidermolysis Bullosa Therapeutics is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Epidermolysis Bullosa Therapeutics is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Epidermolysis Bullosa Therapeutics is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Epidermolysis Bullosa Therapeutics players cover Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the "Epidermolysis Bullosa Therapeutics Industry Forecast" looks at past sales and reviews total world Epidermolysis Bullosa Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Epidermolysis Bullosa Therapeutics sales for 2025 through 2031. With Epidermolysis Bullosa Therapeutics sales broken down by

region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Epidermolysis Bullosa Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Epidermolysis Bullosa Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Epidermolysis Bullosa Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Epidermolysis Bullosa Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Epidermolysis Bullosa Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Epidermolysis Bullosa Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Epidermolysis Bullosa Therapeutics market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

EB-201

FCX-007

ICX-RHY

INM-750

Others

Segmentation by Application:

Clinic

Hospital

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Birken AG

Fibrocell Science, Inc.

GlaxoSmithKline Plc

InMed Pharmaceuticals Inc.

Karus Therapeutics Limited

ProQR Therapeutics N.V.

RegeneRx Biopharmaceuticals, Inc.

Scioderm, Inc.

Stratatech Corporation

TWi Pharmaceuticals, Inc.

WAVE Life Sciences Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Epidermolysis Bullosa Therapeutics market?

What factors are driving Epidermolysis Bullosa Therapeutics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Epidermolysis Bullosa Therapeutics market opportunities vary by end market size?

How does Epidermolysis Bullosa Therapeutics break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Epidermolysis Bullosa Therapeutics Annual Sales 2020-2031
- 2.1.2 World Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Geographic Region, 2020, 2024 & 2031
- 2.1.3 World Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Country/Region, 2020, 2024 & 2031

2.2 Epidermolysis Bullosa Therapeutics Segment by Type

- 2.2.1 EB-201
- 2.2.2 FCX-007
- 2.2.3 ICX-RHY
- 2.2.4 INM-750
- 2.2.5 Others

2.3 Epidermolysis Bullosa Therapeutics Sales by Type

- 2.3.1 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2020-2025)
- 2.3.2 Global Epidermolysis Bullosa Therapeutics Revenue and Market Share by Type (2020-2025)
- 2.3.3 Global Epidermolysis Bullosa Therapeutics Sale Price by Type (2020-2025)

2.4 Epidermolysis Bullosa Therapeutics Segment by Application

- 2.4.1 Clinic
- 2.4.2 Hospital
- 2.4.3 Others

2.5 Epidermolysis Bullosa Therapeutics Sales by Application

- 2.5.1 Global Epidermolysis Bullosa Therapeutics Sale Market Share by Application

(2020-2025)

2.5.2 Global Epidermolysis Bullosa Therapeutics Revenue and Market Share by Application (2020-2025)

2.5.3 Global Epidermolysis Bullosa Therapeutics Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Epidermolysis Bullosa Therapeutics Breakdown Data by Company

3.1.1 Global Epidermolysis Bullosa Therapeutics Annual Sales by Company (2020-2025)

3.1.2 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2020-2025)

3.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue by Company (2020-2025)

3.2.1 Global Epidermolysis Bullosa Therapeutics Revenue by Company (2020-2025)

3.2.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Company (2020-2025)

3.3 Global Epidermolysis Bullosa Therapeutics Sale Price by Company

3.4 Key Manufacturers Epidermolysis Bullosa Therapeutics Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Epidermolysis Bullosa Therapeutics Product Location Distribution

3.4.2 Players Epidermolysis Bullosa Therapeutics Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR EPIDERMOLYSIS BULLOSA THERAPEUTICS BY GEOGRAPHIC REGION

4.1 World Historic Epidermolysis Bullosa Therapeutics Market Size by Geographic Region (2020-2025)

4.1.1 Global Epidermolysis Bullosa Therapeutics Annual Sales by Geographic Region (2020-2025)

4.1.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic Epidermolysis Bullosa Therapeutics Market Size by Country/Region (2020-2025)

4.2.1 Global Epidermolysis Bullosa Therapeutics Annual Sales by Country/Region (2020-2025)

4.2.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue by Country/Region (2020-2025)

4.3 Americas Epidermolysis Bullosa Therapeutics Sales Growth

4.4 APAC Epidermolysis Bullosa Therapeutics Sales Growth

4.5 Europe Epidermolysis Bullosa Therapeutics Sales Growth

4.6 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales Growth

5 AMERICAS

5.1 Americas Epidermolysis Bullosa Therapeutics Sales by Country

5.1.1 Americas Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)

5.1.2 Americas Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025)

5.2 Americas Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025)

5.3 Americas Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Epidermolysis Bullosa Therapeutics Sales by Region

6.1.1 APAC Epidermolysis Bullosa Therapeutics Sales by Region (2020-2025)

6.1.2 APAC Epidermolysis Bullosa Therapeutics Revenue by Region (2020-2025)

6.2 APAC Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025)

6.3 APAC Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Epidermolysis Bullosa Therapeutics by Country

7.1.1 Europe Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)

7.1.2 Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025)

7.2 Europe Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025)

7.3 Europe Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Epidermolysis Bullosa Therapeutics by Country

8.1.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)

8.1.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025)

8.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025)

8.3 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Epidermolysis Bullosa Therapeutics

10.3 Manufacturing Process Analysis of Epidermolysis Bullosa Therapeutics

10.4 Industry Chain Structure of Epidermolysis Bullosa Therapeutics

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Epidermolysis Bullosa Therapeutics Distributors

11.3 Epidermolysis Bullosa Therapeutics Customer

12 WORLD FORECAST REVIEW FOR EPIDERMOLYSIS BULLOSA THERAPEUTICS BY GEOGRAPHIC REGION

12.1 Global Epidermolysis Bullosa Therapeutics Market Size Forecast by Region

12.1.1 Global Epidermolysis Bullosa Therapeutics Forecast by Region (2026-2031)

12.1.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global Epidermolysis Bullosa Therapeutics Forecast by Type (2026-2031)

12.7 Global Epidermolysis Bullosa Therapeutics Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Birken AG

13.1.1 Birken AG Company Information

13.1.2 Birken AG Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.1.3 Birken AG Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.1.4 Birken AG Main Business Overview

13.1.5 Birken AG Latest Developments

13.2 Fibrocell Science, Inc.

13.2.1 Fibrocell Science, Inc. Company Information

13.2.2 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.2.4 Fibrocell Science, Inc. Main Business Overview

13.2.5 Fibrocell Science, Inc. Latest Developments

13.3 GlaxoSmithKline Plc

13.3.1 GlaxoSmithKline Plc Company Information

13.3.2 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.3.4 GlaxoSmithKline Plc Main Business Overview

13.3.5 GlaxoSmithKline Plc Latest Developments

13.4 InMed Pharmaceuticals Inc.

13.4.1 InMed Pharmaceuticals Inc. Company Information

13.4.2 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.4.4 InMed Pharmaceuticals Inc. Main Business Overview

13.4.5 InMed Pharmaceuticals Inc. Latest Developments

13.5 Karus Therapeutics Limited

13.5.1 Karus Therapeutics Limited Company Information

13.5.2 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.5.4 Karus Therapeutics Limited Main Business Overview

13.5.5 Karus Therapeutics Limited Latest Developments

13.6 ProQR Therapeutics N.V.

13.6.1 ProQR Therapeutics N.V. Company Information

13.6.2 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.6.4 ProQR Therapeutics N.V. Main Business Overview

13.6.5 ProQR Therapeutics N.V. Latest Developments

13.7 RegeneRx Biopharmaceuticals, Inc.

13.7.1 RegeneRx Biopharmaceuticals, Inc. Company Information

13.7.2 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics

Product Portfolios and Specifications

13.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.7.4 RegeneRx Biopharmaceuticals, Inc. Main Business Overview

13.7.5 RegeneRx Biopharmaceuticals, Inc. Latest Developments

13.8 Scioderm, Inc.

13.8.1 Scioderm, Inc. Company Information

13.8.2 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.8.4 Scioderm, Inc. Main Business Overview

13.8.5 Scioderm, Inc. Latest Developments

13.9 Stratatech Corporation

13.9.1 Stratatech Corporation Company Information

13.9.2 Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 Stratatech Corporation Main Business Overview

13.9.5 Stratatech Corporation Latest Developments

13.10 TWi Pharmaceuticals, Inc.

13.10.1 TWi Pharmaceuticals, Inc. Company Information

13.10.2 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.10.4 TWi Pharmaceuticals, Inc. Main Business Overview

13.10.5 TWi Pharmaceuticals, Inc. Latest Developments

13.11 WAVE Life Sciences Ltd.

13.11.1 WAVE Life Sciences Ltd. Company Information

13.11.2 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)

13.11.4 WAVE Life Sciences Ltd. Main Business Overview

13.11.5 WAVE Life Sciences Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Epidermolysis Bullosa Therapeutics Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Epidermolysis Bullosa Therapeutics Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of EB-201

Table 4. Major Players of FCX-007

Table 5. Major Players of ICX-RHY

Table 6. Major Players of INM-750

Table 7. Major Players of Others

Table 8. Global Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025) & (K Pcs)

Table 9. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2020-2025)

Table 10. Global Epidermolysis Bullosa Therapeutics Revenue by Type (2020-2025) & (\$ million)

Table 11. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2020-2025)

Table 12. Global Epidermolysis Bullosa Therapeutics Sale Price by Type (2020-2025) & (USD/Pcs)

Table 13. Global Epidermolysis Bullosa Therapeutics Sale by Application (2020-2025) & (K Pcs)

Table 14. Global Epidermolysis Bullosa Therapeutics Sale Market Share by Application (2020-2025)

Table 15. Global Epidermolysis Bullosa Therapeutics Revenue by Application (2020-2025) & (\$ million)

Table 16. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2020-2025)

Table 17. Global Epidermolysis Bullosa Therapeutics Sale Price by Application (2020-2025) & (USD/Pcs)

Table 18. Global Epidermolysis Bullosa Therapeutics Sales by Company (2020-2025) & (K Pcs)

Table 19. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2020-2025)

Table 20. Global Epidermolysis Bullosa Therapeutics Revenue by Company (2020-2025) & (\$ millions)

Table 21. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Company (2020-2025)

Table 22. Global Epidermolysis Bullosa Therapeutics Sale Price by Company (2020-2025) & (USD/Pcs)

Table 23. Key Manufacturers Epidermolysis Bullosa Therapeutics Producing Area Distribution and Sales Area

Table 24. Players Epidermolysis Bullosa Therapeutics Products Offered

Table 25. Epidermolysis Bullosa Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 26. New Products and Potential Entrants

Table 27. Market M&A Activity & Strategy

Table 28. Global Epidermolysis Bullosa Therapeutics Sales by Geographic Region (2020-2025) & (K Pcs)

Table 29. Global Epidermolysis Bullosa Therapeutics Sales Market Share Geographic Region (2020-2025)

Table 30. Global Epidermolysis Bullosa Therapeutics Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 31. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Geographic Region (2020-2025)

Table 32. Global Epidermolysis Bullosa Therapeutics Sales by Country/Region (2020-2025) & (K Pcs)

Table 33. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Country/Region (2020-2025)

Table 34. Global Epidermolysis Bullosa Therapeutics Revenue by Country/Region (2020-2025) & (\$ millions)

Table 35. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Country/Region (2020-2025)

Table 36. Americas Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025) & (K Pcs)

Table 37. Americas Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2020-2025)

Table 38. Americas Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025) & (\$ millions)

Table 39. Americas Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025) & (K Pcs)

Table 40. Americas Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025) & (K Pcs)

Table 41. APAC Epidermolysis Bullosa Therapeutics Sales by Region (2020-2025) & (K Pcs)

Table 42. APAC Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2020-2025)

Table 43. APAC Epidermolysis Bullosa Therapeutics Revenue by Region (2020-2025) & (\$ millions)

Table 44. APAC Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025) & (K Pcs)

Table 45. APAC Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025) & (K Pcs)

Table 46. Europe Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025) & (K Pcs)

Table 47. Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025) & (\$ millions)

Table 48. Europe Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025) & (K Pcs)

Table 49. Europe Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025) & (K Pcs)

Table 50. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025) & (K Pcs)

Table 51. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2020-2025)

Table 52. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025) & (K Pcs)

Table 53. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025) & (K Pcs)

Table 54. Key Market Drivers & Growth Opportunities of Epidermolysis Bullosa Therapeutics

Table 55. Key Market Challenges & Risks of Epidermolysis Bullosa Therapeutics

Table 56. Key Industry Trends of Epidermolysis Bullosa Therapeutics

Table 57. Epidermolysis Bullosa Therapeutics Raw Material

Table 58. Key Suppliers of Raw Materials

Table 59. Epidermolysis Bullosa Therapeutics Distributors List

Table 60. Epidermolysis Bullosa Therapeutics Customer List

Table 61. Global Epidermolysis Bullosa Therapeutics Sales Forecast by Region (2026-2031) & (K Pcs)

Table 62. Global Epidermolysis Bullosa Therapeutics Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 63. Americas Epidermolysis Bullosa Therapeutics Sales Forecast by Country (2026-2031) & (K Pcs)

Table 64. Americas Epidermolysis Bullosa Therapeutics Annual Revenue Forecast by

Country (2026-2031) & (\$ millions)

Table 65. APAC Epidermolysis BullosaTherapeutics SalesForecast by Region
(2026-2031) & (K Pcs)

Table 66. APAC Epidermolysis BullosaTherapeutics Annual RevenueForecast by
Region (2026-2031) & (\$ millions)

Table 67. Europe Epidermolysis BullosaTherapeutics SalesForecast by Country
(2026-2031) & (K Pcs)

Table 68. Europe Epidermolysis BullosaTherapeutics RevenueForecast by Country
(2026-2031) & (\$ millions)

Table 69. Middle East & Africa Epidermolysis BullosaTherapeutics SalesForecast by
Country (2026-2031) & (K Pcs)

Table 70. Middle East & Africa Epidermolysis BullosaTherapeutics RevenueForecast by
Country (2026-2031) & (\$ millions)

Table 71. Global Epidermolysis BullosaTherapeutics SalesForecast byType
(2026-2031) & (K Pcs)

Table 72. Global Epidermolysis BullosaTherapeutics RevenueForecast byType
(2026-2031) & (\$ millions)

Table 73. Global Epidermolysis BullosaTherapeutics SalesForecast by Application
(2026-2031) & (K Pcs)

Table 74. Global Epidermolysis BullosaTherapeutics RevenueForecast by Application
(2026-2031) & (\$ millions)

Table 75. Birken AG Basic Information, Epidermolysis BullosaTherapeutics
Manufacturing Base, Sales Area and Its Competitors

Table 76. Birken AG Epidermolysis BullosaTherapeutics Product Portfolios and
Specifications

Table 77. Birken AG Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$
Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Birken AG Main Business

Table 79. Birken AG Latest Developments

Table 80.Fibrocell Science, Inc. Basic Information, Epidermolysis BullosaTherapeutics
Manufacturing Base, Sales Area and Its Competitors

Table 81.Fibrocell Science, Inc. Epidermolysis BullosaTherapeutics Product Portfolios
and Specifications

Table 82.Fibrocell Science, Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs),
Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83.Fibrocell Science, Inc. Main Business

Table 84.Fibrocell Science, Inc. Latest Developments

Table 85. GlaxoSmithKline Plc Basic Information, Epidermolysis BullosaTherapeutics
Manufacturing Base, Sales Area and Its Competitors

Table 86. GlaxoSmithKline Plc Epidermolysis BullosaTherapeutics Product Portfolios and Specifications

Table 87. GlaxoSmithKline Plc Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. GlaxoSmithKline Plc Main Business

Table 89. GlaxoSmithKline Plc Latest Developments

Table 90. InMed Pharmaceuticals Inc. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors

Table 91. InMed Pharmaceuticals Inc. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications

Table 92. InMed Pharmaceuticals Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. InMed Pharmaceuticals Inc. Main Business

Table 94. InMed Pharmaceuticals Inc. Latest Developments

Table 95. KarusTherapeutics Limited Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors

Table 96. KarusTherapeutics Limited Epidermolysis BullosaTherapeutics Product Portfolios and Specifications

Table 97. KarusTherapeutics Limited Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. KarusTherapeutics Limited Main Business

Table 99. KarusTherapeutics Limited Latest Developments

Table 100. ProQRTherapeutics N.V. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors

Table 101. ProQRTherapeutics N.V. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications

Table 102. ProQRTherapeutics N.V. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. ProQRTherapeutics N.V. Main Business

Table 104. ProQRTherapeutics N.V. Latest Developments

Table 105. RegeneRx Biopharmaceuticals, Inc. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors

Table 106. RegeneRx Biopharmaceuticals, Inc. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications

Table 107. RegeneRx Biopharmaceuticals, Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 108. RegeneRx Biopharmaceuticals, Inc. Main Business

Table 109. RegeneRx Biopharmaceuticals, Inc. Latest Developments

Table 110. Scioderm, Inc. Basic Information, Epidermolysis BullosaTherapeutics

Manufacturing Base, Sales Area and Its Competitors

Table 111. Scioderm, Inc. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications

Table 112. Scioderm, Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 113. Scioderm, Inc. Main Business

Table 114. Scioderm, Inc. Latest Developments

Table 115. Stratatech Corporation Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors

Table 116. Stratatech Corporation Epidermolysis BullosaTherapeutics Product Portfolios and Specifications

Table 117. Stratatech Corporation Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 118. Stratatech Corporation Main Business

Table 119. Stratatech Corporation Latest Developments

Table 120. TWi Pharmaceuticals, Inc. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors

Table 121. TWi Pharmaceuticals, Inc. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications

Table 122. TWi Pharmaceuticals, Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 123. TWi Pharmaceuticals, Inc. Main Business

Table 124. TWi Pharmaceuticals, Inc. Latest Developments

Table 125. WAVE Life Sciences Ltd. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors

Table 126. WAVE Life Sciences Ltd. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications

Table 127. WAVE Life Sciences Ltd. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 128. WAVE Life Sciences Ltd. Main Business

Table 129. WAVE Life Sciences Ltd. Latest Developments

LIST OFFIGURES

Figure 1. Picture of Epidermolysis BullosaTherapeutics

Figure 2. Epidermolysis BullosaTherapeutics Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Epidermolysis Bullosa Therapeutics Sales Growth Rate 2020-2031 (K Pcs)

Figure 7. Global Epidermolysis Bullosa Therapeutics Revenue Growth Rate 2020-2031 (\$ millions)

Figure 8. Epidermolysis Bullosa Therapeutics Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Figure 9. Epidermolysis Bullosa Therapeutics Sales Market Share by Country/Region (2024)

Figure 10. Epidermolysis Bullosa Therapeutics Sales Market Share by Country/Region (2020, 2024 & 2031)

Figure 11. Product Picture of EB-201

Figure 12. Product Picture of FCX-007

Figure 13. Product Picture of ICX-RHY

Figure 14. Product Picture of INM-750

Figure 15. Product Picture of Others

Figure 16. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2025

Figure 17. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2020-2025)

Figure 18. Epidermolysis Bullosa Therapeutics Consumed in Clinic

Figure 19. Global Epidermolysis Bullosa Therapeutics Market: Clinic (2020-2025) & (K Pcs)

Figure 20. Epidermolysis Bullosa Therapeutics Consumed in Hospital

Figure 21. Global Epidermolysis Bullosa Therapeutics Market: Hospital (2020-2025) & (K Pcs)

Figure 22. Epidermolysis Bullosa Therapeutics Consumed in Others

Figure 23. Global Epidermolysis Bullosa Therapeutics Market: Others (2020-2025) & (K Pcs)

Figure 24. Global Epidermolysis Bullosa Therapeutics Sale Market Share by Application (2024)

Figure 25. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application in 2025

Figure 26. Epidermolysis Bullosa Therapeutics Sales by Company in 2025 (K Pcs)

Figure 27. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Company in 2025

Figure 28. Epidermolysis Bullosa Therapeutics Revenue by Company in 2025 (\$ millions)

Figure 29. Global Epidermolysis BullosaTherapeutics Revenue Market Share by Company in 2025

Figure 30. Global Epidermolysis BullosaTherapeutics Sales Market Share by Geographic Region (2020-2025)

Figure 31. Global Epidermolysis BullosaTherapeutics Revenue Market Share by Geographic Region in 2025

Figure 32. Americas Epidermolysis BullosaTherapeutics Sales 2020-2025 (K Pcs)

Figure 33. Americas Epidermolysis BullosaTherapeutics Revenue 2020-2025 (\$ millions)

Figure 34. APAC Epidermolysis BullosaTherapeutics Sales 2020-2025 (K Pcs)

Figure 35. APAC Epidermolysis BullosaTherapeutics Revenue 2020-2025 (\$ millions)

Figure 36. Europe Epidermolysis BullosaTherapeutics Sales 2020-2025 (K Pcs)

Figure 37. Europe Epidermolysis BullosaTherapeutics Revenue 2020-2025 (\$ millions)

Figure 38. Middle East & Africa Epidermolysis BullosaTherapeutics Sales 2020-2025 (K Pcs)

Figure 39. Middle East & Africa Epidermolysis BullosaTherapeutics Revenue 2020-2025 (\$ millions)

Figure 40. Americas Epidermolysis BullosaTherapeutics Sales Market Share by Country in 2025

Figure 41. Americas Epidermolysis BullosaTherapeutics Revenue Market Share by Country (2020-2025)

Figure 42. Americas Epidermolysis BullosaTherapeutics Sales Market Share byType (2020-2025)

Figure 43. Americas Epidermolysis BullosaTherapeutics Sales Market Share by Application (2020-2025)

Figure 44. United States Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 45. Canada Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 46. Mexico Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 47. Brazil Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 48. APAC Epidermolysis BullosaTherapeutics Sales Market Share by Region in 2025

Figure 49. APAC Epidermolysis BullosaTherapeutics Revenue Market Share by Region (2020-2025)

Figure 50. APAC Epidermolysis BullosaTherapeutics Sales Market Share byType (2020-2025)

Figure 51. APAC Epidermolysis BullosaTherapeutics Sales Market Share by Application (2020-2025)

Figure 52. China Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 53. Japan Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 54. South Korea Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 55. Southeast Asia Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 56. India Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 57. Australia Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 58. ChinaTaiwan Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 59. Europe Epidermolysis BullosaTherapeutics Sales Market Share by Country in 2025

Figure 60. Europe Epidermolysis BullosaTherapeutics Revenue Market Share by Country (2020-2025)

Figure 61. Europe Epidermolysis BullosaTherapeutics Sales Market Share byType (2020-2025)

Figure 62. Europe Epidermolysis BullosaTherapeutics Sales Market Share by Application (2020-2025)

Figure 63. Germany Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 64. France Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 65. UK Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 66. Italy Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 67. Russia Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 68. Middle East & Africa Epidermolysis BullosaTherapeutics Sales Market Share by Country (2020-2025)

Figure 69. Middle East & Africa Epidermolysis BullosaTherapeutics Sales Market Share byType (2020-2025)

Figure 70. Middle East & Africa Epidermolysis BullosaTherapeutics Sales Market Share

by Application (2020-2025)

Figure 71. Egypt Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 72. South Africa Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 73. Israel Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 74. Turkey Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 75. GCC Countries Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 (\$ millions)

Figure 76. Manufacturing Cost Structure Analysis of Epidermolysis BullosaTherapeutics in 2025

Figure 77. Manufacturing Process Analysis of Epidermolysis BullosaTherapeutics

Figure 78. Industry Chain Structure of Epidermolysis BullosaTherapeutics

Figure 79. Channels of Distribution

Figure 80. Global Epidermolysis BullosaTherapeutics Sales MarketForecast by Region (2026-2031)

Figure 81. Global Epidermolysis BullosaTherapeutics Revenue Market ShareForecast by Region (2026-2031)

Figure 82. Global Epidermolysis BullosaTherapeutics Sales Market ShareForecast byType (2026-2031)

Figure 83. Global Epidermolysis BullosaTherapeutics Revenue Market ShareForecast byType (2026-2031)

Figure 84. Global Epidermolysis BullosaTherapeutics Sales Market ShareForecast by Application (2026-2031)

Figure 85. Global Epidermolysis BullosaTherapeutics Revenue Market ShareForecast by Application (2026-2031)

I would like to order

Product name: Global Epidermolysis Bullosa Therapeutics Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G4FD14A7E168EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4FD14A7E168EN.html>